Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice.
e12661Background: Neoadjuvant treatment is one of cornerstones of HER2 directed treatment in breast cancer. Today it is considered that patients with complete pathological response (pCR) to neoadjuvant therapy have a better disease-free survival and overall survival, especially with Her2-positive breast cancer. Current standard is use of dual anti-HER2 blockade, but this therapeutic approach in real life is often inaccessible, particularly in countries with limited resources. Aim of this study was to investigate neoadjuvant effects of trastuzumab + pertuzumab in patients with locally advanced Her2-positive disease in a country with limited resources. Methods: During the period 2017-2018, we identified 27 patients with locally advanced Her2 positive breast cancer. All patients were treated with neoadjuvant therapy that included trastuzumab and pertuzumab and conventional chemotherapy regimens. All patients underwent surgery and a pathologist evaluated pCR using MD Anderson Residual Burden Calculator (RCB)....